toolName,toolType,_pmid,_doi,_publicationTitle,_year,_confidence,_usageType,nf_specific,completeness_score,priority,strainNomenclature,animalModelGeneticDisorder,animalModelOfManifestation,targetAntigen,hostOrganism,clonality,organ,cellLineGeneticDisorder,cellLineManifestation,cellLineCategory,insertName,vectorType,vectorBackbone,promoter,softwareName,softwareType,softwareVersion,sourceRepository,modelType,derivationSource,cellTypes,organoidType,modelSystemType,patientDiagnosis,hostStrain,tumorType,assessmentName,assessmentType,targetPopulation,diseaseSpecific,numberOfItems,_context,filter_reason
B6N-Tyrc-Brd/BrdCrCrl,animal_models,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,False,1.00,Medium,B6N-Tyrc-Brd/BrdCrCrl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,injecting 1 × 10 5 cells into the medial flank 4-week-old male B6N-Tyrc-Brd/BrdCrCrl mice (Charles Rivers),Wildtype/control with no known disease: B6N-Tyrc-Brd/BrdCrCrl
"athymic nude mice (Charles River, Stock No. 490)",animal_models,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,1.00,Medium,"athymic nude mice (Charles River, Stock No. 490)",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"8-week-old athymic nude mice (Charles River, Stock No. 490) underwent surgery to implant pNF progenitor cells","Wildtype/control with no known disease: athymic nude mice (Charles River, Stock No. 490)"
K14Cre,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,K14Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14Cre (Dassule et al. 2000), K14CreERT (Vasioukhin et al. 1999), TyrCreERT2 (Bosenberg et al. 2006)... mice were purchased from the Jackson Laboratory",Wildtype/control with no known disease: K14Cre
K14CreERT,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,K14CreERT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14Cre (Dassule et al. 2000), K14CreERT (Vasioukhin et al. 1999), TyrCreERT2 (Bosenberg et al. 2006)... mice were purchased from the Jackson Laboratory",Wildtype/control with no known disease: K14CreERT
TyrCreERT2,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,TyrCreERT2,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14Cre (Dassule et al. 2000), K14CreERT (Vasioukhin et al. 1999), TyrCreERT2 (Bosenberg et al. 2006)... mice were purchased from the Jackson Laboratory",Wildtype/control with no known disease: TyrCreERT2
R26-rtTA,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,R26-rtTA,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"R26-rtTA (Belteki et al. 2005), and tetO-DTA (Lee et al. 1998) mice were purchased from the Jackson Laboratory",Wildtype/control with no known disease: R26-rtTA
tetO-DTA,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,tetO-DTA,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"R26-rtTA (Belteki et al. 2005), and tetO-DTA (Lee et al. 1998) mice were purchased from the Jackson Laboratory",Wildtype/control with no known disease: tetO-DTA
K14-Scf,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,K14-Scf,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,K14-Scf (Kunisada et al. 1998a) was kindly provided by Dr. John Harris (University of Massachusetts Medical School),Wildtype/control with no known disease: K14-Scf
Krox20Cre,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,Krox20Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20Cre (Voiculescu et al. 2000), DhhCre (Skucas et al. 2013), PLPCreERT2 (Leone et al. 2003)... were described previously",Wildtype/control with no known disease: Krox20Cre
DhhCre,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,DhhCre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20Cre (Voiculescu et al. 2000), DhhCre (Skucas et al. 2013), PLPCreERT2 (Leone et al. 2003)... were described previously",Wildtype/control with no known disease: DhhCre
PLPCreERT2,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,PLPCreERT2,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20Cre (Voiculescu et al. 2000), DhhCre (Skucas et al. 2013), PLPCreERT2 (Leone et al. 2003)... were described previously",Wildtype/control with no known disease: PLPCreERT2
CMVCreERT,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,CMVCreERT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CMVCreERT (Hayashi and McMahon 2002), R26-LacZ, and R26-YFP were described previously",Wildtype/control with no known disease: CMVCreERT
R26-LacZ,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,R26-LacZ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CMVCreERT (Hayashi and McMahon 2002), R26-LacZ, and R26-YFP were described previously",Wildtype/control with no known disease: R26-LacZ
R26-YFP,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,R26-YFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CMVCreERT (Hayashi and McMahon 2002), R26-LacZ, and R26-YFP were described previously",Wildtype/control with no known disease: R26-YFP
Long Evans,animal_models,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,1.00,Medium,Long Evans,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Twenty-seven female Long Evans rats (age 12 weeks, approximate weight 200 g, Charles River. Wilmington, MA) were used in the experiments.",Wildtype/control with no known disease: Long Evans
Myf5 Cre,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,False,1.00,Medium,Myf5 Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse lines used in this study were described before: Myf5 Cre,Wildtype/control with no known disease: Myf5 Cre
Lbx1 Cre,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,False,1.00,Medium,Lbx1 Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse lines used in this study were described before: Myf5 Cre, Lbx1 Cre",Wildtype/control with no known disease: Lbx1 Cre
Rosa26 mTmG,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,False,1.00,Medium,Rosa26 mTmG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse lines used in this study were described before: Myf5 Cre, Lbx1 Cre, Nf1 flox, and Rosa26 mTmG",Wildtype/control with no known disease: Rosa26 mTmG
NOD.CB17-Prkdc/NCrCrl,animal_models,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,NOD.CB17-Prkdc/NCrCrl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female NOD SCID (NOD.CB17-Prkdc/NCrCrl) mice from Charles River Laboratories were housed in barrier facilities designed for immune-compromised animals.,Wildtype/control with no known disease: NOD.CB17-Prkdc/NCrCrl
Balb/c,animal_models,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,Experimental Usage,False,1.00,Medium,Balb/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Initial range-finding studies employed female Balb/c mice (Taconic Laboratories).,Wildtype/control with no known disease: Balb/c
FVB/C57BL/6,animal_models,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,FVB/C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Syngeneic immune-competent FVB/C57BL/6 mice, both male and female, 10–12 weeks old, are used for implantation of the mouse NF2 −/− Schwann cell line.",Wildtype/control with no known disease: FVB/C57BL/6
nude mice (nu/nu),animal_models,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,nude mice (nu/nu),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"When using human VS cell lines, such as the established human HEI-193 cell line or other immortalized human VS cell lines, immune-deficient mice (e.g., nude mice (nu/nu) or NOD SCID mice) should be used.",Wildtype/control with no known disease: nude mice (nu/nu)
NOD SCID,animal_models,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,NOD SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"When using human VS cell lines, such as the established human HEI-193 cell line or other immortalized human VS cell lines, immune-deficient mice (e.g., nude mice (nu/nu) or NOD SCID mice) should be used.",Wildtype/control with no known disease: NOD SCID
Nu/Nu,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,1.00,Medium,Nu/Nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3 × 10^6 p53−/−; Myc; Cas9 cells were injected into flanks of 6-8-week old, female, NCI Nu/Nu mice (Taconic)",Wildtype/control with no known disease: Nu/Nu
p53 flox/flox,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,p53 flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p53 mice were crossed with Albumin-Cre mice (Jackson Laboratories) flox/flox,Wildtype/control with no known disease: p53 flox/flox
Albumin-Cre,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,Albumin-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p53 mice were crossed with Albumin-Cre mice (Jackson Laboratories) flox/flox,Wildtype/control with no known disease: Albumin-Cre
Kras LSL-G12D/+,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,Kras LSL-G12D/+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kras G12D;shp53 mouse cholangiocarcinoma was generated as in using Kras LSL-G12D/+ liver progenitor cells,Wildtype/control with no known disease: Kras LSL-G12D/+
K14 Cre,animal_models,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,1.00,Medium,K14 Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14 Cre mice were available from the Jackson Laboratory (Bar Harbor, ME). All mice were maintained on a mix C57bl/6 background.",Wildtype/control with no known disease: K14 Cre
zebrafish,animal_models,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,Experimental Usage,False,1.00,Medium,zebrafish,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RNA transcripts were injected into zebrafish embryos at the single-cell stage. GFP signals in the zebrafish embryos indicated synthetic RNA expression,Wildtype/control with no known disease: zebrafish
Nf1 flox/flox,animal_models,PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,1.00,Medium,Nf1 flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,littermate control Nf1 flox/flox (CTL) mice were maintained on an inbred C57BL/6 background,Wildtype/control with no known disease: Nf1 flox/flox
Col2.3Cre,animal_models,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.85,Experimental Usage,False,1.00,Medium,Col2.3Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Col2.3Cre transgenic mice were generated as described elsewhere. In this model, the 2.3 α1(I) Collagen promoter is used to selectively drive Cre expression",Wildtype/control with no known disease: Col2.3Cre
ROSA26,animal_models,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.85,Experimental Usage,False,1.00,Medium,ROSA26,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Col2.3Cre transgenic mice were crossed with ROSA26 reporter mice. LacZ staining was performed to assess Cre recombination,Wildtype/control with no known disease: ROSA26
p53floxE2–10,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,Experimental Usage,False,1.00,Medium,p53floxE2–10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The floxed p53 alleles (p53floxE2–10) and (p53LSLR172H) have been described previously,Wildtype/control with no known disease: p53floxE2–10
p53LSLR172H,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,Experimental Usage,False,1.00,Medium,p53LSLR172H,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The floxed p53 alleles (p53floxE2–10) and (p53LSLR172H) have been described previously,Wildtype/control with no known disease: p53LSLR172H
hGFAP-cre+; p53floxE2–10/floxE2–10,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,False,1.00,Medium,hGFAP-cre+; p53floxE2–10/floxE2–10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p53 null CKO (p53ΔE2–10 CKO, hGFAP-cre+; p53floxE2–10/floxE2–10) and p53R172H CKO",Wildtype/control with no known disease: hGFAP-cre+; p53floxE2–10/floxE2–10
hGFAP-cre+; p53LSLR172H/floxE2–10,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,False,1.00,Medium,hGFAP-cre+; p53LSLR172H/floxE2–10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p53R172H CKO (hGFAP-cre+; p53LSLR172H/floxE2–10) mice analyzed in this study,Wildtype/control with no known disease: hGFAP-cre+; p53LSLR172H/floxE2–10
C57BL/6,animal_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Wild-type C57BL/6 and B6J.129(B6N)-Gt(ROSA)26Sor (JAX stock #026175) tm1(CAG-cas9*,-EGFP)Fezh/J mice strains were used",Wildtype/control with no known disease: C57BL/6
"B6J.129(B6N)-Gt(ROSA)26Sor tm1(CAG-cas9*,-EGFP)Fezh/J",animal_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Experimental Usage,False,1.00,Medium,"B6J.129(B6N)-Gt(ROSA)26Sor tm1(CAG-cas9*,-EGFP)Fezh/J",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"B6J.129(B6N)-Gt(ROSA)26Sor (JAX stock #026175) tm1(CAG-cas9*,-EGFP)Fezh/J mice strains were used for derivation of wild-type and Cas9/GFP-expressing organoids","Wildtype/control with no known disease: B6J.129(B6N)-Gt(ROSA)26Sor tm1(CAG-cas9*,-EGFP)Fezh/J"
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOD scid gamma (NSG; NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice were used. Transplantation experiments were performed,Wildtype/control with no known disease: NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ
1016 tuba1a:GFP,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,1016 tuba1a:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Wildtype/control with no known disease: 1016 tuba1a:GFP
gfap:GFP,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,gfap:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Wildtype/control with no known disease: gfap:GFP
hsp70:DN-MAML-GFP,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,hsp70:DN-MAML-GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Wildtype/control with no known disease: hsp70:DN-MAML-GFP
gfap:mCherry,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,gfap:mCherry,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Wildtype/control with no known disease: gfap:mCherry
tp1:mCherry,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,tp1:mCherry,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Wildtype/control with no known disease: tp1:mCherry
athymic nude mice,animal_models,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,Experimental Usage,False,1.00,Medium,athymic nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Athymic nude mice were purchased from Charles River Laboratories (stock no. 553).,Wildtype/control with no known disease: athymic nude mice
C57Bl/6,animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,Experimental Usage,False,1.00,Medium,C57Bl/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For subcutaneous CT26 tumour implantation, LPS and CLP experiments, female C57Bl/6 and BALB/C mice of 6–8 weeks were purchased from Harlan Laboratories.",Wildtype/control with no known disease: C57Bl/6
BALB/C,animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,Experimental Usage,False,1.00,Medium,BALB/C,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For subcutaneous CT26 tumour implantation, LPS and CLP experiments, female C57Bl/6 and BALB/C mice of 6–8 weeks were purchased from Harlan Laboratories.",Wildtype/control with no known disease: BALB/C
"NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ",animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,1.00,Medium,"NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For the CART19 treatment, NSG-SGM3 (NSGS) mice (stock number 013062) were purchased from the Jackson Laboratory.","Wildtype/control with no known disease: NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ"
LysMcre Thfl/fl,animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,1.00,Medium,LysMcre Thfl/fl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"LysMcre mice were purchased from Jackson Laboratory (stock number 004781), in which a nuclear-localized Cre recombinase was inserted into the first coding exon of the lysozyme 2 (Lyz2 or LysM) gene",Wildtype/control with no known disease: LysMcre Thfl/fl
NSG,animal_models,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,False,1.00,Medium,NSG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"150,000 cells in 3 µl were implanted in the sciatic nerve of NSG mice (female, 6–10 weeks old)",Wildtype/control with no known disease: NSG
CB17 SCID,animal_models,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,False,1.00,Medium,CB17 SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"subcutaneously injected into both flanks of 6- to 8-week-old female CB17 SCID mice (Taconic, RRID: MSR_TAC:cb17sc)",Wildtype/control with no known disease: CB17 SCID
y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*],animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,1.00,Medium,y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*],No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,germline source of Cas9: y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*] (Bloomington Stock #54591),Wildtype/control with no known disease: y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*]
Crl:NU(NCr)‐Foxn1nu,animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,Experimental Usage,False,1.00,Medium,Crl:NU(NCr)‐Foxn1nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,subcutaneously into the right flank of male CD‐1 nude mice (Athymic Nude Mice obtained from Charles River (Crl:NU(NCr)‐Foxn1nu)),Wildtype/control with no known disease: Crl:NU(NCr)‐Foxn1nu
C57BL/6J,animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toxicity studies were performed using CD‐1 mice and C57BL/6J Inbred Mice (JAX® Mice Strain),Wildtype/control with no known disease: C57BL/6J
FVB,animal_models,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,Experimental Usage,False,1.00,Medium,FVB,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"WT FVB mice were obtained from Jackson Labs (Bar Harbor, ME)",Wildtype/control with no known disease: FVB
nu/nu,animal_models,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"implanted in 1 µl culture medium into the sciatic nerve of athymic mice (nu/nu, 5-week-old females; Cox 7 breeding facility, MGH)",Wildtype/control with no known disease: nu/nu
Rosa26-LSL-Cas9 knockin,animal_models,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.95,Experimental Usage,False,1.00,Medium,Rosa26-LSL-Cas9 knockin,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Twenty mice of Rosa26‐LSL‐Cas9 knockin were purchased from Jackson Laboratory (Strain #:024857, USA) and successfully bred in our lab.",Wildtype/control with no known disease: Rosa26-LSL-Cas9 knockin
mdx,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,False,1.00,Medium,mdx,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...two mouse models of genetic muscle disease: a type 1 neurofibromatosis (NF1) limb-mesenchyme knockout (Nf1Prx1-/-) and a muscular dystrophy mouse (mdx)...,Wildtype/control with no known disease: mdx
C57BL/6,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.85,Experimental Usage,False,1.00,Medium,C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C57BL/6 mice (B6) and mice (NF1) were bred in-house at the Transgenic Facility at The Children's Hospital at Westmead...,Wildtype/control with no known disease: C57BL/6
Prx1-Cre,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,False,1.00,Medium,Prx1-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...the NF1 mice bred from the Prx1-Cre transgenic mice and the Nf1flox/flox mice...,Wildtype/control with no known disease: Prx1-Cre
B10 mdx,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,False,1.00,Medium,B10 mdx,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The mdx mice (B10 mdx) were sourced from Australian Bioresources (ABR, Moss Vale). As these mice are on a C57BL/10 background...",Wildtype/control with no known disease: B10 mdx
NG2-EYFP mice,animal_models,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,1.00,Medium,NG2-EYFP mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NG2-EYFP mice, which carry a YFP fluorescent protein gene instead of a NG2 gene, are healthy and fertile and do not show any obvious phenotype",Wildtype/control with no known disease: NG2-EYFP mice
C57Bl6/J,animal_models,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.85,Experimental Usage,False,1.00,Medium,C57Bl6/J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mice for cell cultures were obtained from breedings of C57Bl6/J mice (Janvier Labs, France)",Wildtype/control with no known disease: C57Bl6/J
nu/nu,animal_models,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,injected subcutaneously into the right flanks of 6 to 8-week-old female athymic nude (nu/nu) mice (Harlan),Wildtype/control with no known disease: nu/nu
NOD/SCID,animal_models,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,NOD/SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Four-month-old male NOD/SCID mice were anesthetized with isofluorane and orthotopically implanted with 1 mm3 piece of explant tumour,Wildtype/control with no known disease: NOD/SCID
Lats1/2-mut,animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,Lats1/2-mut,No known disease,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse MPNST mice (Lats1/2-mut) were generated by crossing floxed Lats1Lats2 mice with Dhh-Cre mice (JAX 012929) to obtain Lats1/2-mut offspring,Wildtype/control with no known disease: Lats1/2-mut
CAG-tdTomato (stock no. 007909),animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,CAG-tdTomato (stock no. 007909),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The reporter mice CAG-tdTomato (stock no. 007909), CAG-CAT-EGFP (ccGFP) (stock no. 024636) C57/Bl6;FVBN obtained from The Jackson Laboratory",Wildtype/control with no known disease: CAG-tdTomato (stock no. 007909)
CAG-CAT-EGFP (stock no. 024636),animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,CAG-CAT-EGFP (stock no. 024636),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The reporter mice CAG-tdTomato (stock no. 007909), CAG-CAT-EGFP (ccGFP) (stock no. 024636) C57/Bl6;FVBN obtained from The Jackson Laboratory",Wildtype/control with no known disease: CAG-CAT-EGFP (stock no. 024636)
NBSGW (JAX 026622),animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,NBSGW (JAX 026622),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female immunodeficient NBSGW (JAX 026622) mice of 6 to 8 weeks were used for allograft transplantations,Wildtype/control with no known disease: NBSGW (JAX 026622)
NCR nude,animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,NCR nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female athymic NCR nude mice of 6 to 8 weeks were used for xenograft transplantations,Wildtype/control with no known disease: NCR nude
PLPCre-ERT2,animal_models,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.85,Experimental Usage,False,1.00,Medium,PLPCre-ERT2,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For conditional ablation of NF1, we used a tamoxifen-inducible Cre line, the PLPCre-ERT2 transgenic mice",Wildtype/control with no known disease: PLPCre-ERT2
ROSA26R,animal_models,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.85,Experimental Usage,False,1.00,Medium,ROSA26R,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The LacZ reporter mice, ROSA26R, were obtained from the Jackson Laboratories",Wildtype/control with no known disease: ROSA26R
Thy1::ChR2-YFP (line 20),animal_models,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,Experimental Usage,False,1.00,Medium,Thy1::ChR2-YFP (line 20),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Thy1::ChR2-YFP (line 20) and Nlgn3KO mice were acquired from the Jackson Laboratory (012350 and 008394, respectively)",Wildtype/control with no known disease: Thy1::ChR2-YFP (line 20)
Nlgn3KO,animal_models,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,Experimental Usage,False,1.00,Medium,Nlgn3KO,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Thy1::ChR2-YFP (line 20) and Nlgn3KO mice were acquired from the Jackson Laboratory (012350 and 008394, respectively)",Wildtype/control with no known disease: Nlgn3KO
C57BL/6J,animal_models,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wildtype C57BL/6J and Nf1 mice littermates were housed and bred in the Indiana University Laboratory Animal Research Center,Wildtype/control with no known disease: C57BL/6J
NOD-Rag1 null IL2rg,animal_models,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,1.00,Medium,NOD-Rag1 null IL2rg,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Immunodeficient NOD-Rag1 null IL2rg mice (The Jackson Laboratory) received approximately 3 million cells via subcutaneous flank injection,Wildtype/control with no known disease: NOD-Rag1 null IL2rg
NOD-SCID-Prkdc scid,animal_models,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,1.00,Medium,NOD-SCID-Prkdc scid,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,non-obese diabetic severe combined immune deficiency spontaneous male mice (NOD-SCID-Prkdc scid) received 5 × 10^6 cells,Wildtype/control with no known disease: NOD-SCID-Prkdc scid
B6.Cg/NTac-Foxn1nu NE10,animal_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,False,1.00,Medium,B6.Cg/NTac-Foxn1nu NE10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Athymic (B6.Cg/NTac-Foxn1nu NE10) mice were purchased from Taconic Laboratories,Wildtype/control with no known disease: B6.Cg/NTac-Foxn1nu NE10
Foxn1 nu/nu,animal_models,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,Foxn1 nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.5 million cells in serum-free DMEM with 33% Matrigel Basement Membrane (BD Biosciences) were injected into the back flanks of athymic Foxn1 nu/nu mice (Charles Rivers Laboratory),Wildtype/control with no known disease: Foxn1 nu/nu
Balb/c,animal_models,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,1.00,Medium,Balb/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CT26 and 4T1 subcutaneous grafts in Balb/c mice,Wildtype/control with no known disease: Balb/c
Fbxw11tm1a(KOMP)Wtsi,animal_models,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,False,1.00,Medium,Fbxw11tm1a(KOMP)Wtsi,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Fbxw11 heterozygous (Fbxw11+/–, C57BL/6NTac) mice were from Knockout Mouse Project (KOMP)",Wildtype/control with no known disease: Fbxw11tm1a(KOMP)Wtsi
Fbxw11fl/fl,animal_models,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,False,1.00,Medium,Fbxw11fl/fl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fbxw11fl/fl (exon 4 targeted) mice were generated from the Fbxw11tm1a(KOMP)Wtsi strain by FLP-FRT recombination,Wildtype/control with no known disease: Fbxw11fl/fl
p19 knockout,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,Experimental Usage,False,1.00,Medium,p19 knockout,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mice with the p19 mutation were a kind gift from Dr. Martine Roussel at St. Jude's Children's Research Hospital,Wildtype/control with no known disease: p19 knockout
Mx1-Cre,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,Experimental Usage,False,1.00,Medium,Mx1-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mx1-Cre, Nf1 flox, and Nf1 fcr (Nf1 knockout) mice have been described previously",Wildtype/control with no known disease: Mx1-Cre
C57BL/6J,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Recipient C57BL/6J × 129/Sv F1 mice were sublethally irradiated,Wildtype/control with no known disease: C57BL/6J
129/Sv,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,Experimental Usage,False,1.00,Medium,129/Sv,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,recipient animals were generated by crossing 129/Sv mice to C57BL/6J mice,Wildtype/control with no known disease: 129/Sv
Wisconsin Miniature SwineTM,animal_models,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.95,Development,False,1.00,Medium,Wisconsin Miniature SwineTM,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The Wisconsin Miniature SwineTM (WMSTM) was developed to address these shortcomings. The WMSTM porcine model grows slower, reaching and maintaining human sizes at adulthood.",Wildtype/control with no known disease: Wisconsin Miniature SwineTM
WMSTM-WT,animal_models,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,False,1.00,Medium,WMSTM-WT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The WMSTM-WT and WMSTM-FH lines are housed at the University of Wisconsin Swine Research and Teaching Center,Wildtype/control with no known disease: WMSTM-WT
WMSTM-FH,animal_models,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,False,1.00,Medium,WMSTM-FH,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The WMSTM-WT and WMSTM-FH lines are housed at the University of Wisconsin Swine Research and Teaching Center,Wildtype/control with no known disease: WMSTM-FH
Lats1 lox/lox Lats2 lox/lox,animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Lats1 lox/lox Lats2 lox/lox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Lats1 mice ( lox/lox Lats2 lox/lox Heallen et al., 2011 ), on a mixed C57/Bl6;129Sv;FVBN background, were crossed with Dhh -Cre",Wildtype/control with no known disease: Lats1 lox/lox Lats2 lox/lox
Dhh-Cre,animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Dhh-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"were crossed with Dhh -Cre ( Jaegle et al., 2003 ) mice or Plp1 -CreERT (Stock 005975) mice, both on a C57/Bl6 background",Wildtype/control with no known disease: Dhh-Cre
Plp1-CreERT (Stock 005975),animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Plp1-CreERT (Stock 005975),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Plp1 -CreERT (Stock 005975) mice, both on a C57/Bl6 background to obtain Lats1 ;Cre lox/+ Lats2 lox/+ +/− mice",Wildtype/control with no known disease: Plp1-CreERT (Stock 005975)
CAG-tdTomato (Stock 007909),animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,CAG-tdTomato (Stock 007909),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The reporter mice CAG-tdTomato (Stock 007909), CAG-CATEGFP (ccGFP) (Stock 024636) were obtained from the Jackson Laboratory",Wildtype/control with no known disease: CAG-tdTomato (Stock 007909)
CAG-CATEGFP (Stock 024636),animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,CAG-CATEGFP (Stock 024636),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CAG-CATEGFP (ccGFP) (Stock 024636) were obtained from the Jackson Laboratory,Wildtype/control with no known disease: CAG-CATEGFP (Stock 024636)
Taz lox/lox Yap1 lox/lox,animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Taz lox/lox Yap1 lox/lox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Taz ( lox/lox Yap1 lox/lox Deng et al., 2017 ) mice, on a mixed C57/Bl6;129Sv;FVBN background",Wildtype/control with no known disease: Taz lox/lox Yap1 lox/lox
Tie2cre,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,1.00,Medium,Tie2cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tie2cre (4128) and VE-cadherin cre (VEcre, 6137) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA)",Wildtype/control with no known disease: Tie2cre
VE-cadherin cre,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,1.00,Medium,VE-cadherin cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tie2cre (4128) and VE-cadherin cre (VEcre, 6137) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA)",Wildtype/control with no known disease: VE-cadherin cre
standardised femoral rat fracture model,animal_models,PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.75,Citation Only,False,1.00,Low,standardised femoral rat fracture model,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The geometrical domain of the computational model is deduced from the real callus geometry at three weeks post-fracture in a standardised femoral rat fracture model,Wildtype/control with no known disease: standardised femoral rat fracture model
MacGreen (Csf1r-eGFP),animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,MacGreen (Csf1r-eGFP),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,bred onto a wild type or MacGreen (Csf1r-eGFP; [ 58 ] C57/BL6 background,Wildtype/control with no known disease: MacGreen (Csf1r-eGFP)
CX3CR1-CreER,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,CX3CR1-CreER,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CX3CR1-CreER [ 71 ] were intercrossed with Nf1 flox/flox,Wildtype/control with no known disease: CX3CR1-CreER
R26R-EYFP,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,R26R-EYFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercrossed with Nf1 flox/flox [ 1 ] and R26R-EYFP mice [ 63 ],Wildtype/control with no known disease: R26R-EYFP
hGFAP-Cre,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,hGFAP-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hGFAP-Cre +/+ were intercrossed with Nf1 flox/flox,Wildtype/control with no known disease: hGFAP-Cre
BALB/c nude,animal_models,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,Experimental Usage,False,1.00,Medium,BALB/c nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RT4-D6P2T or HEI-193 cells were subcutaneously inoculated into the back of 4-week-old BALB/c nude mice (male),Wildtype/control with no known disease: BALB/c nude
Rabl6m/m C57Bl/6N,animal_models,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,1.00,Medium,Rabl6m/m C57Bl/6N,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse embryonic fibroblasts (MEFs) from wildtype and Rabl6m/m C57Bl/6N mice were isolated,Wildtype/control with no known disease: Rabl6m/m C57Bl/6N
NRG,animal_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,NRG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nonobese diabetic Rag gamma (NRG; no. 007799) female mice were purchased from the Jackson Laboratory,Wildtype/control with no known disease: NRG
w CS10,animal_models,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,1.00,Medium,w CS10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 P1 mutation was backcrossed six generations into the w CS10 genetic background and w CS10 flies were used as controls.,Wildtype/control with no known disease: w CS10
Cnp-Cre; R26-lsl-SB11; T2/Onc15,animal_models,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Cnp-Cre; R26-lsl-SB11; T2/Onc15,No known disease,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Triple transgenic mice (Cnp-Cre; R26-lsl-SB11; T2/Onc15) undergo insertional mutagenesis in Schwann cells.,Wildtype/control with no known disease: Cnp-Cre; R26-lsl-SB11; T2/Onc15
Postn-Cre,animal_models,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,Experimental Usage,False,1.00,Medium,Postn-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Postn-Cre transgenic and conditional Nf2flox/flox knocking alleles were obtained,Wildtype/control with no known disease: Postn-Cre
JAX:002019,animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,JAX:002019,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NF1-proficient and NF1-deficient engineered clones were injected into the flanks of 6- to 7-week-old athymic nude mice (RRID: JAX:002019),Wildtype/control with no known disease: JAX:002019
JAX:007799,animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,JAX:007799,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"S462-TY cells (1.0 × 106) in 50% Matrigel (BD Biosciences) were injected subcutaneously into the flank of 6- to 7-week-old NOD-Rag1 null IL2rg null, NOD rag gamma, NOD-RG (NRG) mice (RRID: JAX:007799)",Wildtype/control with no known disease: JAX:007799
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ,animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For the patient-derived xenograft (PDX) MPNST model, tumor tissue was implanted subcutaneously directly into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice",Wildtype/control with no known disease: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
Balb/cAnNRj-Foxn1nu/Foxn1nu,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,Balb/cAnNRj-Foxn1nu/Foxn1nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Balb/c Nude (Balb/cAnNRj-Foxn1nu/Foxn1nu, Janvier), Foxn1 (Nu/Nu) Nude (Crl:NU-Foxn1nu, Charles River)",Wildtype/control with no known disease: Balb/cAnNRj-Foxn1nu/Foxn1nu
Crl:NU-Foxn1nu,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,Crl:NU-Foxn1nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Foxn1 (Nu/Nu) Nude (Crl:NU-Foxn1nu, Charles River), SHO ® (SCID Hairless Outbred, Crl:SHO-PrkdcscidHrhr, Charles River)",Wildtype/control with no known disease: Crl:NU-Foxn1nu
Crl:SHO-PrkdcscidHrhr,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,Crl:SHO-PrkdcscidHrhr,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SHO ® (SCID Hairless Outbred, Crl:SHO-PrkdcscidHrhr, Charles River) and Shorn (ShrN NOD SCID, NOD.Cg-PrkdcscidHrhr/NCrHsd, Harlan)",Wildtype/control with no known disease: Crl:SHO-PrkdcscidHrhr
NOD.Cg-PrkdcscidHrhr/NCrHsd,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-PrkdcscidHrhr/NCrHsd,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Shorn (ShrN NOD SCID, NOD.Cg-PrkdcscidHrhr/NCrHsd, Harlan) mice were scheduled for xenotransplantations",Wildtype/control with no known disease: NOD.Cg-PrkdcscidHrhr/NCrHsd
loxP-Pten (Pten f),animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,Experimental Usage,False,1.00,Medium,loxP-Pten (Pten f),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27), p53 f (28), or p53 f ; Pten f females",Wildtype/control with no known disease: loxP-Pten (Pten f)
p53 f,animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,Experimental Usage,False,1.00,Medium,p53 f,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27), p53 f (28), or p53 f ; Pten f females",Wildtype/control with no known disease: p53 f
athymic nude,animal_models,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,athymic nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"using athymic nude six-week-old male mice, in which no tumor was engrafted",Wildtype/control with no known disease: athymic nude
athymic Ncr Nu/Nu,animal_models,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,False,1.00,Medium,athymic Ncr Nu/Nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Xenografts were developed in male athymic Ncr Nu/Nu mice (National Cancer Institute, NIH, Bethesda, MD)",Wildtype/control with no known disease: athymic Ncr Nu/Nu
nude mice,animal_models,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.8,Experimental Usage,False,1.00,Medium,nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1×10 6 FC-1801 cells were suspended in Ca/Mg-free PBS and injected subcutaneously into the right flank of nude mice.,Wildtype/control with no known disease: nude mice
BALB/c nu/nu,animal_models,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,1.00,Medium,BALB/c nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2×10^6 cells were injected subcutaneously into flanks of 5-week old nude mice (BALB/c nu/nu),Wildtype/control with no known disease: BALB/c nu/nu
#002019,animal_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,#002019,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Athymic nude (# 002019) and NOD scid gamma (NSG, # 005557) female mice were purchased from the Jackson Laboratory",Wildtype/control with no known disease: #002019
#005557,animal_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,#005557,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Athymic nude (# 002019) and NOD scid gamma (NSG, # 005557) female mice were purchased from the Jackson Laboratory",Wildtype/control with no known disease: #005557
athymic female nude mice,animal_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,False,1.00,Medium,athymic female nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"We injected 5×10^5 mouse sphere cells/injection subcutaneously into athymic female nude mice (Harlan, Indianapolis, IN)",Wildtype/control with no known disease: athymic female nude mice
Wnt-1-Cre+,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,Wnt-1-Cre+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For conditional deletion of Nf1 we used Wnt-1-Cre (+ Danielian et al., 1998)",Wildtype/control with no known disease: Wnt-1-Cre+
3.9Periostin-Cre+,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,3.9Periostin-Cre+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3.9Periostin-Cre (+ Lindsley et al., 2007)",Wildtype/control with no known disease: 3.9Periostin-Cre+
P0a-Cre+,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,P0a-Cre+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"P0a-Cre (+ Giovannini et al., 2000) mice",Wildtype/control with no known disease: P0a-Cre+
Ink4a-/-,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,Ink4a-/-,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Compound mutant mice were generated by mating Nf1 mice with +/− Ink4a mice (−/− Sharpless et al., 2001)",Wildtype/control with no known disease: Ink4a-/-
Ink4aArf-/-,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,Ink4aArf-/-,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ink4aArf mice (−/− Serrano et al., 1996)",Wildtype/control with no known disease: Ink4aArf-/-
C57BL/6JOlaHsd,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,C57BL/6JOlaHsd,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Experimental mice were obtained by crossing Nf1 mice (in C57BL/6JOlaHsd background),Wildtype/control with no known disease: C57BL/6JOlaHsd
129T2/SvEmsJ,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,129T2/SvEmsJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"with 129T2/SvEmsJ (Jackson Laboratories, Bar Harbor, ME, USA)",Wildtype/control with no known disease: 129T2/SvEmsJ
G12V H-Ras,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,G12V H-Ras,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+/− H-Ras mice in C57BL/6JOlaHsd background were obtained by crossing heterozygous G12V H-Ras mice,Wildtype/control with no known disease: G12V H-Ras
NOD scid gamma,animal_models,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,1.00,Medium,NOD scid gamma,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOD scid gamma (NSG) female and male mice were purchased from Johns Hopkins University Animal Resources Core,Wildtype/control with no known disease: NOD scid gamma
Tg(4xhre-tata:eGFP)ia,animal_models,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,False,1.00,Medium,Tg(4xhre-tata:eGFP)ia,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The male Zebrafish reporter line for HIF1α Tg(4xhre-tata:eGFP)ia was outcrossed with female wild-type Zebrafish,Wildtype/control with no known disease: Tg(4xhre-tata:eGFP)ia
Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D,animal_models,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,False,1.00,Medium,Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D,No known disease,pancreatic adenocarcinoma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"generating the final transgenic line Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D, as described",Wildtype/control with no known disease: Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D
nu/nu Balb/c,animal_models,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu Balb/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Athymic nude mice (female, nu/nu Balb/c, 6 weeks, 20 g) were obtained from Charles River Laboratories (Sulzfeld, Germany).",Wildtype/control with no known disease: nu/nu Balb/c
Prss56Cre/Cre,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,Prss56Cre/Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The following mouse lines were used and genotyped as described in the original publications: Prss56Cre/Cre, R26tdTom/tdTom; Prss56Cre/Cre",Wildtype/control with no known disease: Prss56Cre/Cre
R26tdTom/tdTom,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,R26tdTom/tdTom,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The following mouse lines were used and genotyped as described in the original publications: Prss56Cre/Cre, R26tdTom/tdTom; Prss56Cre/Cre",Wildtype/control with no known disease: R26tdTom/tdTom
B6D2F1,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,B6D2F1,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1+/−; and B6D2F1 (https://janvier-labs.com/en/fiche_produit/b6d2f1-mouse/),Wildtype/control with no known disease: B6D2F1
nude,animal_models,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,False,1.00,Medium,nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Experiments were performed in 8-week-old nude female mice (Charles River, Wilmington, MA)",Wildtype/control with no known disease: nude
p16 Ink4a*/*,animal_models,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,Experimental Usage,False,1.00,Medium,p16 Ink4a*/*,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf2 flox2/flox2 mice (4) on the FVB/N background were bred to p16 Ink4a*/* mice (11) on a FVB/N/129Ola mixed background,Wildtype/control with no known disease: p16 Ink4a*/*
nu/nu,animal_models,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Athymic nu/nu mice were anesthetized in isoflurane and injected s.c. with 10^6 STS26T cells in the left flank,Wildtype/control with no known disease: nu/nu
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_models,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"6- to 8-week-old NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, strain #:005557, Jackson Laboratory or Johns Hopkins Oncology Animal Facility) and SCID female mice were used for in vivo efficacy studies",Wildtype/control with no known disease: NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ
C.B-17/IcrHsd-Prkdc scid,animal_models,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.9,Experimental Usage,False,1.00,Medium,C.B-17/IcrHsd-Prkdc scid,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NSG and SCID (C.B-17/IcrHsd-Prkdc scid , Envigo) female mice were used for in vivo efficacy studies",Wildtype/control with no known disease: C.B-17/IcrHsd-Prkdc scid
"B6-Olig2tm2(TVA,cre)Rth/J",animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.95,Experimental Usage,False,1.00,Medium,"B6-Olig2tm2(TVA,cre)Rth/J",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Olig2-Cre mice (B6-Olig2 tm2 (TVA, cre)Rth /J; Jackson Laboratory; [ 20 ])","Wildtype/control with no known disease: B6-Olig2tm2(TVA,cre)Rth/J"
GFAP-Cre,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,False,1.00,Medium,GFAP-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Olig2-Cre mice (B6-Olig2 tm2 (TVA, cre)Rth /J; Jackson Laboratory; [ 20 ]) and GFAP-Cre mice [ 32 ]",Wildtype/control with no known disease: GFAP-Cre
B6.Cg-Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.95,Experimental Usage,False,1.00,Medium,B6.Cg-Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rosa-GREEN mice (B6.Cg- Gt(ROSA)26Sor tm(CAGZsGreen1)Hze+ / J; Jackson Laboratory),Wildtype/control with no known disease: B6.Cg-Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J
Eed f/f,animal_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,Experimental Usage,False,1.00,Medium,Eed f/f,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Eed-isogenic mouse MPNST cells were generated as follows: Eed f/f mice (67, 68) were bred with PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f mice",Wildtype/control with no known disease: Eed f/f
CB-17 SCID,animal_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,CB-17 SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Eed-isogenic cells were infected with sgRNA lentiviruses for additional knockout of Cdkn2b followed by subcutaneous implantation into CB-17 SCID mice (Taconic, RRID:IMSR_TAC:cb17sc)",Wildtype/control with no known disease: CB-17 SCID
Plp-Cre,animal_models,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,Experimental Usage,False,1.00,Medium,Plp-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inducible Plp-Cre (66) and Nf1 fl/+ (67) mice were maintained on a pure C57BL/6 background,Wildtype/control with no known disease: Plp-Cre
NU/NU,animal_models,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,NU/NU,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Subcutaneous allografts were performed by implanting 5 million JW18.2 or JW23.3 MPNST allografts cells into the flanks of 5–6-week-old female NU/NU mice (Harlan Sprague Dawley),Wildtype/control with no known disease: NU/NU
Postn-cre,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,Postn-cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Periostin-cre (Postn-cre) were crossed with floxed Nf2 gene (Postn-cre;Nf2) as previously described.,Wildtype/control with no known disease: Postn-cre
Rosa26 LSL-Neurod1 (R26ND1),animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,Rosa26 LSL-Neurod1 (R26ND1),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rosa26 (LSL-Neurod1 R26ND1) line that induces Neurod1 expression via cre-mediated excision of a stop codon,Wildtype/control with no known disease: Rosa26 LSL-Neurod1 (R26ND1)
tg(Atoh1-cre)8,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,1.00,Medium,tg(Atoh1-cre)8,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we used the following mouse lines: tg(Atoh1-cre)8; R26smo and tg(Neurod1-cre)29 to generate fast and slow growing medulloblastoma,Wildtype/control with no known disease: tg(Atoh1-cre)8
tg(Neurod1-cre)29,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,1.00,Medium,tg(Neurod1-cre)29,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we used the following mouse lines: tg(Atoh1-cre)8; R26smo and tg(Neurod1-cre)29 to generate fast and slow growing medulloblastoma,Wildtype/control with no known disease: tg(Neurod1-cre)29
R26LacZ,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.8,Experimental Usage,False,1.00,Medium,R26LacZ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we used the widely available R26LacZ reporter mice to verify that the Postn-cre effectively and exclusively recombines,Wildtype/control with no known disease: R26LacZ
1016 tuba1a:GFP,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,1016 tuba1a:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) 1016 tuba1a:GFP Fausett and Goldman, 2006",Wildtype/control with no known disease: 1016 tuba1a:GFP
gfap:GFP,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,gfap:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) gfap:GFP Kassen et al., 2007",Wildtype/control with no known disease: gfap:GFP
tp1:mCherry,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,tp1:mCherry,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) tp1:mCherry Parsons et al., 2009",Wildtype/control with no known disease: tp1:mCherry
zop:nsfb-EGFP,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,zop:nsfb-EGFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) zop:nsfb-EGFP Montgomery et al., 2010",Wildtype/control with no known disease: zop:nsfb-EGFP
hsp70:ca-Alk5,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,hsp70:ca-Alk5,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) hsp70:ca-Alk5 Zhou et al., 2011",Wildtype/control with no known disease: hsp70:ca-Alk5
hsp70:tgfb1b,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Development,False,1.00,Medium,hsp70:tgfb1b,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) hsp70:tgfb1b This paper; Figure 5 tgfb1b expressed under the hsp70 promoter",Wildtype/control with no known disease: hsp70:tgfb1b
hsp70:tgfb3,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Development,False,1.00,Medium,hsp70:tgfb3,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) hsp70:tgfb3 This paper; Figure 4 tgfb3 expressed under the hsp70 promoter",Wildtype/control with no known disease: hsp70:tgfb3
Long-Evans,animal_models,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.95,Experimental Usage,False,1.00,Medium,Long-Evans,No known disease,Optic Pathway Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Twenty-four domestic rats of the Long-Evans strain (age 4 weeks with approximate weight of 150 g) were used as control and test recipients,Wildtype/control with no known disease: Long-Evans
fl Trp53 (#008462),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,False,1.00,Medium,fl Trp53 (#008462),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Wildtype/control with no known disease: fl Trp53 (#008462)
fl Plp-CreER (#005975),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,False,1.00,Medium,fl Plp-CreER (#005975),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Wildtype/control with no known disease: fl Plp-CreER (#005975)
T Nestin-Cre (#003771),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,False,1.00,Medium,T Nestin-Cre (#003771),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Wildtype/control with no known disease: T Nestin-Cre (#003771)
SCID,animal_models,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.9,Experimental Usage,False,1.00,Medium,SCID,No known disease,Immunodeficiency for xenograft studies,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mice with severe combined immunodeficiency (SCID) were used as recipients of human neurofibroma xenotransplants,Wildtype/control with no known disease: SCID
Nf1 flox/flox,animal_models,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,1.00,Medium,Nf1 flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,control littermate Nf1 flox/flox (WT) mice were maintained on an inbred C57BL/6 background,Wildtype/control with no known disease: Nf1 flox/flox
Tg(HOTCre:Cas9),animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,False,1.00,Medium,Tg(HOTCre:Cas9),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center), Tg(HOTCre:Cas9) (a kind gift from Dr Wenbiao Chen, Vanderbilt University School of Medicine)",Wildtype/control with no known disease: Tg(HOTCre:Cas9)
Tg(-7.2kb-sox10:mRFP),animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,False,1.00,Medium,Tg(-7.2kb-sox10:mRFP),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center), Tg(HOTCre:Cas9) (a kind gift from Dr Wenbiao Chen, Vanderbilt University School of Medicine, Nashville, TN, USA), Tg(−7.2kb-sox10:mRFP)",Wildtype/control with no known disease: Tg(-7.2kb-sox10:mRFP)
ABWT,animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,Experimental Usage,False,1.00,Medium,ABWT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center),Wildtype/control with no known disease: ABWT
NOD-Rag1 null IL2rg (NRG),animal_models,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,1.00,Medium,NOD-Rag1 null IL2rg (NRG),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tumor tissue was implanted dorsally into 5- to 6-week-old NOD- Rag1 null IL2rg (NRG) mice.,Wildtype/control with no known disease: NOD-Rag1 null IL2rg (NRG)
Nf1flox/flox,animal_models,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,Nf1flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1 +/- GFAP CKO ( Nf1 flox/mut ;GFAP-Cre,  Nf1 -CKO) and littermate control ( Nf1 flox/flox ; CTL) mice were maintained on an inbred C57BL/6 background",Wildtype/control with no known disease: Nf1flox/flox
FVB/N.129-Cdkn2atm1Rdp,animal_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,FVB/N.129-Cdkn2atm1Rdp,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p16/p19+/− (01XB2, FVB/N.129-Cdkn2atm1Rdp) mice, obtained from the Mouse Models of Human Cancers Consortium, were crossed to Nf2 mice",Wildtype/control with no known disease: FVB/N.129-Cdkn2atm1Rdp
SCID mice,animal_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,False,1.00,Medium,SCID mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5 × 106 or 1.0 × 106 murine MM cells were injected into the tail vein of recipient SCID mice,Wildtype/control with no known disease: SCID mice
BALB/c,animal_models,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,1.00,Medium,BALB/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The anti-p55 mouse monoclonal antibody was generated by immunizing BALB/c mice with the recombinant SH3-GUK segment,Wildtype/control with no known disease: BALB/c
Sprague‒Dawley,animal_models,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,1.00,Medium,Sprague‒Dawley,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NSCs were obtained from the fetal brains of embryonic Day 14 pregnant Sprague‒Dawley rats (Experimental Animal Center of Southern Medical University, Guangzhou, China)",Wildtype/control with no known disease: Sprague‒Dawley
R26 LacZR,animal_models,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,R26 LacZR,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The R26 LacZR allele was introduced to the control, Nf1 hGFAP CKO, Nf1 Math1 CKO, Nf1 L7 CKO and Nf1 NcreER CKO mice as a reporter",Wildtype/control with no known disease: R26 LacZR
Fmr1 KO,animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,False,1.00,Medium,Fmr1 KO,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Generation of the Fmr1 KO (Mientjes et al., 2006)...Calyces from both Tsc1(+/-) and from Fmr1 knock-out (KO) mice showed increased volume",Wildtype/control with no known disease: Fmr1 KO
H-ras G12V,animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,False,1.00,Medium,H-ras G12V,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Generation of the...H-ras mice (G12V Schuhmacher et al., 2008) has been described previously",Wildtype/control with no known disease: H-ras G12V
Tsc1 (+/-),animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,False,1.00,Medium,Tsc1 (+/-),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tsc1 animals were obtained by crossing the +/- Tsc1 line (f/+ Meikle et al., 2005)...Calyces from both Tsc1(+/-) and from Fmr1 knock-out (KO) mice showed increased volume",Wildtype/control with no known disease: Tsc1 (+/-)
CAGG-Cre,animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.8,Experimental Usage,False,1.00,Medium,CAGG-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tsc1 animals were obtained by crossing the +/- Tsc1 line (f/+ Meikle et al., 2005) once with CAGG-Cre mice to obtain germ-line deletion",Wildtype/control with no known disease: CAGG-Cre
NSG,animal_models,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,False,1.00,Medium,NSG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tumor tissue was implanted s.c. into the flank of 5- to 6-week-old NSG mice (The Jackson Laboratory).,Wildtype/control with no known disease: NSG
C57BL/6N,animal_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,C57BL/6N,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,viral injection into the left sciatic nerve of wild-type C57BL/6N mice,Wildtype/control with no known disease: C57BL/6N
NOD scid gamma,animal_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,NOD scid gamma,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,injected into the left sciatic nerve of immunodeficient (NOD scid gamma) mice,Wildtype/control with no known disease: NOD scid gamma
NOD RAG1/2−/− IL2Rγ−/−,animal_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,NOD RAG1/2−/− IL2Rγ−/−,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,implanted subcutaneously with Matrigel in immunodeficient NRG (NOD RAG1/2−/− IL2Rγ−/−) mice,Wildtype/control with no known disease: NOD RAG1/2−/− IL2Rγ−/−
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_models,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) male mice (6–8 weeks of age) were obtained from the on-site breeding colony,Wildtype/control with no known disease: NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ
Perceived Stress Scale,clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Perceived Stress Scale,scale,adult,No,,Perceived Stress Scale score of 6 or higher,Generic psychological scale (not NF-specific)
gait test,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,gait test,performance test,all ages,No,,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests","Generic physical performance test, not a validated clinical instrument"
MIA ELISA kit,clinical_assessment_tools,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,MIA ELISA kit,biomarker assay,all ages,Yes,,"The MIA ELISA kit was purchased from (Roche Diagnostics, Indianapolis, IN, USA) and the measurements were conducted",Lab assay/kit misclassified as clinical assessment tool
"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",biomarker assay,all ages,No,,"Levels of circulating sAXL were measured in human plasma using the Human AXL DuoSet ELISA kit (R&D Systems, DY154)",Lab assay/kit misclassified as clinical assessment tool
"Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",biomarker assay,all ages,No,,"Levels of circulating sAXL were measured in mouse plasma using the Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",Lab assay/kit misclassified as clinical assessment tool
"Caspase 3/7 Glo activity (#G8093, Promega)",clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase 3/7 Glo activity (#G8093, Promega)",biomarker assay,all ages,No,,"Caspase 3/7 Glo activity (#G8093, Promega) was measured by luminescence after 24 hours of treatment",Lab assay/kit misclassified as clinical assessment tool
Rating of Overall Stress Scale (ROSS),clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rating of Overall Stress Scale (ROSS),scale,adult,No,,Participants rated their stress in the past month from 0 (not stressed) to 10 (very stressed). This measure was adapted from Leidy et al. [ 31 ].,Generic psychological scale (not NF-specific)
compound motor action potential (CMAP),clinical_assessment_tools,PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,compound motor action potential (CMAP),biomarker assay,all ages,No,,"When significantly reduced, the compound motor action potential (CMAP) – correlating with the number of functional axons – is an indicator for axonal damage.","Generic physical performance test, not a validated clinical instrument"
Perceived Stress Scale (PSS),clinical_assessment_tools,PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Perceived Stress Scale (PSS),scale,adult,No,10.0,The PSS is the most widely used psychological instrument for measuring the perception of stress. Composed of 10 items rated from never to often,Generic psychological scale (not NF-specific)
64-channel Neuroscan system,clinical_assessment_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,64-channel Neuroscan system,biomarker assay,pediatric,No,,"EEG signal was recorded from six parieto-occipital channels (PO3, POZ, PO4, O1, OZ and O2) using a 64-channel Neuroscan system","Hardware device, not a clinical assessment instrument"
Quantikine™ human VEGF immunoassay kit,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Quantikine™ human VEGF immunoassay kit,biomarker assay,pediatric,No,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified at baseline and at steady-state on day 28 ± 1 of cycle 1 using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN)",Lab assay/kit misclassified as clinical assessment tool
Quantikine™ human sVEGFR2 immunoassay kit,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Quantikine™ human sVEGFR2 immunoassay kit,biomarker assay,pediatric,No,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified at baseline and at steady-state on day 28 ± 1 of cycle 1 using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN)",Lab assay/kit misclassified as clinical assessment tool
BBB open-field locomotor test,clinical_assessment_tools,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BBB open-field locomotor test,scale,all ages,No,22.0,"The 22-point (0–21) Basso, Beattie, and Bresnahan (BBB) open-field locomotor test was used to assess hindlimb locomotor function","Generic physical performance test, not a validated clinical instrument"
CNVkit,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CNVkit,Analysis Software,,,,,,,,,,,,,,,,Copy Number Variants were detected and plotted using CNVkit,Generic bioinformatics/stats tool: CNVkit
STRING database,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING database,Database,11.0,https://cn.string-db.org/,,,,,,,,,,,,,,We used the STRING database (version 11.0) (https://cn.string-db.org/),Generic bioinformatics/stats tool: STRING database
Cytoscape,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,3.7.2,,,,,,,,,,,,,,,Cytoscape (version 3.7.2) was used to construct the network,Generic bioinformatics/stats tool: Cytoscape
DESeq2,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Analysis Software,,,,,,,,,,,,,,,,Differential expression analysis was performed with DESeq2 using default settings,Generic bioinformatics/stats tool: DESeq2
CNVkit,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CNVkit,Analysis Software,,,,,,,,,,,,,,,,"Whole exome sequencing (WES), RNA sequencing (RNA-Seq), and copy number analysis (CNVkit) were performed on each sample",Generic bioinformatics/stats tool: CNVkit
Illumina HiSeq4000,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq4000,Other,,,,,,,,,,,,,,,,"Exome libraries were captured with an IDT exome reagent, then pooled with a WGS library for sequencing on an Illumina HiSeq4000 with at least 1000x coverage",Sequencing hardware or generic assay protocol: Illumina HiSeq4000
VarScan2,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel",Generic bioinformatics/stats tool: VarScan2
Strelka2,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Strelka2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel",Generic bioinformatics/stats tool: Strelka2
MuTect2,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MuTect2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel",Generic bioinformatics/stats tool: MuTect2
VEP,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VEP,Analysis Software,version 95,,,,,,,,,,,,,,,"which includes best-practice variant filtering and annotation with VEP (Variant Effect Predictor, version 95)",Generic bioinformatics/stats tool: VEP
edgeR,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,edgeR,Package/Library,,,,,,,,,,,,,,,,Gene counts and transcript counts were normalized by CPM (counts per million) by using edgeR package,Generic bioinformatics/stats tool: edgeR
Illumina NovaSeq6000,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina NovaSeq6000,Other,,,,,,,,,,,,,,,,which were sequenced on the Illumina NovaSeq6000 sequencing machine using S4 flow cells,Sequencing hardware or generic assay protocol: Illumina NovaSeq6000
GATK,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK,Analysis Software,4.1.8.0,,,,,,,,,,,,,,,"Aligned reads in BAM format were processed following the Genome Analysis Toolkit (GATK, version 4.1.8.0) Best Practices workflow",Generic bioinformatics/stats tool: GATK
Strelka2,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Strelka2,Analysis Software,2.9.2,,,,,,,,,,,,,,,"The germline short variant discovery workflow from GATK (version 4.1.8.0; ref. 47), Strelka2 (version 2.9.2; ref. 51)",Generic bioinformatics/stats tool: Strelka2
Annovar,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Annovar,Analysis Software,2018Apr16,,,,,,,,,,,,,,,Annovar (version 2018Apr16) was used to annotate all variants (53),Generic bioinformatics/stats tool: Annovar
LUMPY,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,LUMPY,Analysis Software,0.2.13,,,,,,,,,,,,,,,"LUMPY (version 0.2.13; ref. 56), SvABA (version 1.1.3; ref. 57), and Delly (version 0.8.3; refs. 57, 58)",Generic bioinformatics/stats tool: LUMPY
Delly,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Delly,Analysis Software,0.8.3,,,,,,,,,,,,,,,"LUMPY (version 0.2.13; ref. 56), SvABA (version 1.1.3; ref. 57), and Delly (version 0.8.3; refs. 57, 58)",Generic bioinformatics/stats tool: Delly
STAR,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,2.7.4a,,,,,,,,,,,,,,,Sequencing reads were mapped to the transcriptome using the STAR aligner (version 2.7.4a; ref. 74),Generic bioinformatics/stats tool: STAR
HTSeq,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HTSeq,Analysis Software,0.6.1p1,,,,,,,,,,,,,,,Gene-expression counts were generated using HTSeq (v.0.6.1p1; ref. 75),Generic bioinformatics/stats tool: HTSeq
ARRIBA,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ARRIBA,Analysis Software,2.1.0,,,,,,,,,,,,,,,Gene fusions were detected using ARRIBA (version 2.1.0; ref. 77),Generic bioinformatics/stats tool: ARRIBA
STAR-Fusion,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR-Fusion,Analysis Software,1.10.1,,,,,,,,,,,,,,,"TopHat-fusion (version 2.1.0; ref. 78), EricScript (version 0.5.5; ref. 79), and STAR-Fusion (version 1.10.1; ref. 80)",Generic bioinformatics/stats tool: STAR-Fusion
SAMtools,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAMtools,Analysis Software,1.0,,,,,,,,,,,,,,,SAMtools (version 1.0) is used for sorting the BAM file,Generic bioinformatics/stats tool: SAMtools
GATK,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK,Analysis Software,3.8,,,,,,,,,,,,,,,Single-nucleotide variant is then identified using GATK (version 3.8),Generic bioinformatics/stats tool: GATK
ANNOVAR,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ANNOVAR,Analysis Software,2015Dec,,,,,,,,,,,,,,,subsequently annotated using ANNOVAR (version 2015Dec),Generic bioinformatics/stats tool: ANNOVAR
DESeq2,computational_tools,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2,Package/Library,v1.18.0,,,,,,,,,,,,,,,DESeq2 (v1.18.0) package was used to normalize count data and for differential gene expression analysis,Generic bioinformatics/stats tool: DESeq2
GSEA,computational_tools,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GSEA,Analysis Software,v3.0 beta2,,,,,,,,,,,,,,,Gene set enrichment analysis (GSEA) was performed using GSEA software v3.0 beta2,Generic bioinformatics/stats tool: GSEA
STAR,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,v. 2.5.2a,,,,,,,,,,,,,,,"Sequence reads were aligned to human reference genome Ensembl GRCh37 (v.75), using STAR (v. 2.5.2a)",Generic bioinformatics/stats tool: STAR
edgeR,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,edgeR,Package/Library,v. 3.18.1,,,,,,,,,,,,,,,Differentially expressed genes in pair-wise comparisons were identified by edgeR's quasi-likelihood F test (v. 3.18.1),Generic bioinformatics/stats tool: edgeR
fastQC,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,fastQC,Analysis Software,v.0.10.1,,,,,,,,,,,,,,,Quality checking of sequence reads was assessed by fastQC (v.0.10.1),Generic bioinformatics/stats tool: fastQC
Perseus,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Perseus,Analysis Software,,,,,,,,,,,,,,,,"LFQ data generated by Maxquant were processed using Microsoft Excel and specially developed proteomics software, Perseus",Generic bioinformatics/stats tool: Perseus
bulk RNA sequencing,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bulk RNA sequencing,Analysis Software,,,,,,,,,,,,,,,,"For patients in the institutional cohort whose samples underwent bulk RNA sequencing, whole exome sequencing and spatial transcriptomics profiling",Sequencing hardware or generic assay protocol: bulk RNA sequencing
whole exome sequencing,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,whole exome sequencing,Analysis Software,,,,,,,,,,,,,,,,"For patients in the institutional cohort whose samples underwent bulk RNA sequencing, whole exome sequencing and spatial transcriptomics profiling",Sequencing hardware or generic assay protocol: whole exome sequencing
HumanRef-8_v2 Sentrix BeadChips,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HumanRef-8_v2 Sentrix BeadChips,Analysis Software,,,,,,,,,,,,,,,,Amplified biotinylated cRNA (1.5 µg) was hybridized to HumanRef-8_v2 Sentrix BeadChips.,Sequencing hardware or generic assay protocol: HumanRef-8_v2 Sentrix BeadChips
Ion Ampliseq Designer v3.0,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Ion Ampliseq Designer v3.0,Analysis Software,v3.0,,,,,,,,,,,,,,,"A targeted, multiplex PCR primer panel was designed using the custom Ion Ampliseq Designer v3.0",Sequencing hardware or generic assay protocol: Ion Ampliseq Designer v3.0
Illumina HiSeq X Ten System,computational_tools,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq X Ten System,Analysis Software,,,,,,,,,,,,,,,,"Sequencing was carried out on an Illumina HiSeq X Ten System (Illumina, San Diego, CA, United States)",Sequencing hardware or generic assay protocol: Illumina HiSeq X Ten System
HISAT2,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2,Analysis Software,36,,,,,,,,,,,,,,,"The RNA sequencing data were mapped to the Ensembl Sus Scrofa genome 11.1, release 103 using HISAT2",Generic bioinformatics/stats tool: HISAT2
StringTie,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,StringTie,Analysis Software,37,,,,,,,,,,,,,,,"mapped to the Ensembl Sus Scrofa genome 11.1, release 103 using HISAT2 and quantified with StringTie",Generic bioinformatics/stats tool: StringTie
Illumina Infinium MethylationEPIC BeadChip array,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina Infinium MethylationEPIC BeadChip array,Analysis Software,,,,,,,,,,,,,,,,"Methylation profiling was performed on bisulfite-treated DNA using the Illumina Infinium MethylationEPIC BeadChip array (Illumina, San Diego, USA)",Sequencing hardware or generic assay protocol: Illumina Infinium MethylationEPIC BeadChip array
edgeR,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,edgeR,Package/Library,v.3.22.3,,,,,,,,,,,,,,,Data was normalized by counts-per-million (CPM) and then subjected to trimmed means of M (TMM) using edgeR (v.3.22.3),Generic bioinformatics/stats tool: edgeR
ultra-low-pass whole genome sequencing (ULP-WGS),computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ultra-low-pass whole genome sequencing (ULP-WGS),Analysis Software,,,,,,,,,,,,,,,,This multi-institutional study used fragment size analysis and ultra-low-pass whole genome sequencing (ULP-WGS) of plasma cell-free DNA,Sequencing hardware or generic assay protocol: ultra-low-pass whole genome sequencing (ULP-WGS)
ggplot2,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,ggplot2,Package/Library,v.3.3.5,,,,,,,,,,,,,,,The tSNE plot was visualized with ggplot2 (v.3.3.5),Generic bioinformatics/stats tool: ggplot2
Limma,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Limma,Package/Library,v.3.40.6,,,,,,,,,,,,,,,The lmFit function from the Limma package (v.3.40.6) was applied on a log-transformed b value matrix,Generic bioinformatics/stats tool: Limma
HISAT2,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2,Analysis Software,2.0.3,,,,,,,,,,,,,,,Reads were aligned to GRCh38 using the splice-aware aligner HISAT2 version 2.0.3,Generic bioinformatics/stats tool: HISAT2
Skyline,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Skyline,Analysis Software,4.2.0.19072,,,,,,,,,,,,,,,All PRM data was analyzed by Skyline 4.2.0.19072,Generic bioinformatics/stats tool: Skyline
STAR,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,v2.7.8a,,,,,,,,,,,,,,,RNA sequencing reads were aligned to the hg38 Ensembl release 105 assembly with STAR v2.7.8a,Generic bioinformatics/stats tool: STAR
Illumina EPIC 850K methylation array,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina EPIC 850K methylation array,Analysis Software,,,,,,,,,,,,,,,,We interrogated the methylation profiles of 45 CNFs and 17 PNFs from NF1 subjects with the Illumina EPIC 850K methylation array.,Sequencing hardware or generic assay protocol: Illumina EPIC 850K methylation array
STAR,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,v2.7.0f,,,,,,,,,,,,,,,"Sequencing lanes were merged, followed by alignment with STAR (v2.7.0f) to b37",Generic bioinformatics/stats tool: STAR
edgeR,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,edgeR,Package/Library,v3.27.14,,,,,,,,,,,,,,,Reverse-stranded gene counts were read into R (v3.6.1) using edgeR (v3.27.14),Generic bioinformatics/stats tool: edgeR
ggplot2,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2,Package/Library,v3.2.1,,,,,,,,,,,,,,,"For all correlation plots, data were fit by stat_smooth using loess with span = 1 using ggplot2 (v3.2.1)",Generic bioinformatics/stats tool: ggplot2
MiSeq-M01450,computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MiSeq-M01450,Other,,,,,,,,,,,,,,,,followed by sequencing using the MiSeq‐M01450 instrument (150‐base paired end mode; Illumina),Sequencing hardware or generic assay protocol: MiSeq-M01450
DAVID,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DAVID,Web Application,6.8,,,,,,,,,,,,,,,"The Database for Annotation, Visualization, and Integrated Discovery (DAVID) (Version 6.8, https://david.ncifcrf.gov/) was used to perform GO and KEGG pathway enrichment analysis",Generic bioinformatics/stats tool: DAVID
Cytoscape,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,3.7.0,,,,,,,,,,,,,,,visualized the interaction using Cytoscape software (Version 3.7.0.),Generic bioinformatics/stats tool: Cytoscape
samtools,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,samtools,Analysis Software,,,,,,,,,,,,,,,,a sorted bam file was created with samtools,Generic bioinformatics/stats tool: samtools
bedtools,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bedtools,Analysis Software,,,,,,,,,,,,,,,,Exhaustive coverage metrics were produced using a combination of bedtools and custom R,Generic bioinformatics/stats tool: bedtools
VarScan2,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,Variants...were called using VarScan2 with the following parameters,Generic bioinformatics/stats tool: VarScan2
annovar,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,annovar,Analysis Software,,,,,,,,,,,,,,,,variants were annotated with a combination of annovar and custom scripts,Generic bioinformatics/stats tool: annovar
DeSeq2,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DeSeq2,Package/Library,,,,,,,,,,,,,,,,Differentially expressed genes between GFP+ and GFP- tumor populations were analyzed by paired experiment design in the DeSeq2 package,Generic bioinformatics/stats tool: DeSeq2
samtools,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,samtools,Command-line Tool,v1.17,,,,,,,,,,,,,,,Downsampling was repeated using seed values 0 to 4 in samtools v1.17,Generic bioinformatics/stats tool: samtools
Picard,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Picard,Command-line Tool,v.4.0.1.2,,,,,,,,,,,,,,,"Fragment lengths, extracted from bam files using Picard (v.4.0.1.2)",Generic bioinformatics/stats tool: Picard
MuTect,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MuTect,Analysis Software,,https://github.com/broadinstitute/mutect,,,,,,,,,,,,,,somatic variant calling was performed using either MuTect (https://github.com/broadinstitute/mutect),Generic bioinformatics/stats tool: MuTect
Cytoscape,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cytoscape,Analysis Software,,,,,,,,,,,,,,,,Cytoscape ( 26 ) was used to create a graphic representation of the pink-module,Generic bioinformatics/stats tool: Cytoscape
Illumina Infinium HumanMethylationEPIC (EPIC) array,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina Infinium HumanMethylationEPIC (EPIC) array,Analysis Software,,,,,,,,,,,,,,,,Bisulfite-treated DNA from all tumor samples was then processed for methylation profiling using the Illumina Infinium HumanMethylationEPIC (EPIC) array,Sequencing hardware or generic assay protocol: Illumina Infinium HumanMethylationEPIC (EPIC) array
limma,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma,Package/Library,,,,,,,,,,,,,,,,We performed supervised analysis of methylation data using limma based modeling approach (Bioconductor),Generic bioinformatics/stats tool: limma
Strelka,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Strelka,Analysis Software,v1.0.13,,,,,,,,,,,,,,,"Haplotype Caller, MuTect1 v1.1.7 and Strelka v1.0.13 were run to create raw variant call files",Generic bioinformatics/stats tool: Strelka
Delly,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Delly,Analysis Software,0.8.1,,,,,,,,,,,,,,,Structural variant (SV) prediction for tumor and matched normal pairs was carried out using Delly (version 0.8.1),Generic bioinformatics/stats tool: Delly
FastQC,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FastQC,Analysis Software,0.11.5,,,,,,,,,,,,,,,The quality assessment of the raw reads was carried out using the FastQC tool (version 0.11.5),Generic bioinformatics/stats tool: FastQC
HtSeq,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HtSeq,Analysis Software,0.11.0,,,,,,,,,,,,,,,The RNASeq reads were counted over gene exons using HtSeq (version 0.11.0),Generic bioinformatics/stats tool: HtSeq
DESeq2,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2,Package/Library,1.26.0,,,,,,,,,,,,,,,DEseq2 (DESeq2_1.26.0) was used to normalize and difference in library preparation methods was corrected by limma,Generic bioinformatics/stats tool: DESeq2
edgeR,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,edgeR,Package/Library,,,,,,,,,,,,,,,,Differential gene expression analysis was performed using the R package edgeR in BioConductor,Generic bioinformatics/stats tool: edgeR
GSEA,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GSEA,Analysis Software,3.0,,,,,,,,,,,,,,,Pathways analysis was performed using DEG from indicated pairwise analysis by the Gene Set Enrichment Analysis (GSEA) software from the Broad Institute (version 3.0),Generic bioinformatics/stats tool: GSEA
Cytoscape,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,3.7.2,,,,,,,,,,,,,,,labeled by AutoAnnotate (version 1.2) in Cytoscape (Version 3.7.2),Generic bioinformatics/stats tool: Cytoscape
ANNOVAR,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ANNOVAR,Analysis Software,,,,,,,,,,,,,,,,predicted the functional consequence of missense variants using ANNOVAR which included prediction scores from 20 prediction algorithms,Generic bioinformatics/stats tool: ANNOVAR
Salmon,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Salmon,Analysis Software,,,,,,,,,,,,,,,,raw fastq files were downloaded from Synapse and transcripts were quantified using the Salmon pseudo-alignment tool [36] with Gencode V29 transcriptome.,Generic bioinformatics/stats tool: Salmon
clusterProfiler,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,clusterProfiler,Package/Library,,,,,,,,,,,,,,,,we performed FEA of the strongly associated modules using the clusterProfiler package of the R software,Generic bioinformatics/stats tool: clusterProfiler
STRING,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING,Database,,https://string-db.org/,,,,,,,,,,,,,,The key module genes were uploaded to STRING (https://string-db.org/) to generate the PPI axis,Generic bioinformatics/stats tool: STRING
Cytoscape,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,v3.8.2,,,,,,,,,,,,,,,the results were visualized using the Cytoscape (v3.8.2) software,Generic bioinformatics/stats tool: Cytoscape
limma,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma,Package/Library,,,,,,,,,,,,,,,,DEGs were identified between NF2-Vs and normal nerves using the R package limma,Generic bioinformatics/stats tool: limma
DAVID,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DAVID,Web Application,6.8,,,,,,,,,,,,,,,"ontological analysis using DAVID (Database for Annotation, Visualization, and Integrated Discovery: https://david.ncifcrf.gov ; version 6.8)",Generic bioinformatics/stats tool: DAVID
NextSeq500 instrument (Illumina),computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NextSeq500 instrument (Illumina),Analysis Software,,,,,,,,,,,,,,,,Paired-end sequencing (2x150bp) was performed on a NextSeq500 instrument (Illumina),Sequencing hardware or generic assay protocol: NextSeq500 instrument (Illumina)
SnpEff,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SnpEff,Analysis Software,,,,,,,,,,,,,,,,Variant annotation was performed using SnpEff and included annotations gathered in dbNSFP,Generic bioinformatics/stats tool: SnpEff
Trim Galore,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trim Galore,Analysis Software,,https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/,,,,,,,,,,,,,,All WES/WGS/RNA-seq samples were trimmed and quality controlled via Trim Galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/),Generic bioinformatics/stats tool: Trim Galore
Illumina NextSeq550Dx,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina NextSeq550Dx,Analysis Software,,,,,,,,,,,,,,,,"The samples were then sequenced on an Illumina NextSeq550Dx, which generated paired-end reads of 151 bp.",Sequencing hardware or generic assay protocol: Illumina NextSeq550Dx
salmon,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,salmon,Analysis Software,1.4.0,,,,,,,,,,,,,,,quantified reads to the GENCODE M19 transcriptome using 'salmon' (1.4.0) aligner (RRID: SCR_017036),Generic bioinformatics/stats tool: salmon
DESeq2,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2,Analysis Software,1.24.0,,,,,,,,,,,,,,,Differential gene expression analysis was then conducted with DESeq2 (1.24.0) (RRID: SCR_015687),Generic bioinformatics/stats tool: DESeq2
DNA extraction kit,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,Genomic DNA (gDNA) was extracted from blood or frozen tissue using Qiagen DNeasy Blood & Tissue kit (Qiagen Ca#69506),Non-genetic lab reagent/kit/consumable: DNA extraction kit
TruSeq DNA PCR Free 350bp,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq DNA PCR Free 350bp,Other,,,,,,,,,,,,,,,,,,,,Between 350 and 500 ng of tumor DNA were used to prepare DNA sequencing libraries using the TruSeq DNA PCR Free 350bp kit,Non-genetic lab reagent/kit/consumable: TruSeq DNA PCR Free 350bp
reverse transcription kit,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reverse transcription kit,Other,,,,,,,,,,,,,,,,,,,,"mRNA (5 μg per 50 μL sample) was reverse transcribed using the Gene AMP kit (Perkin-Elmer; Waltham, MA)",Non-genetic lab reagent/kit/consumable: reverse transcription kit
Complete Mini protease inhibitors,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Complete Mini protease inhibitors,Other,,,,,,,,,,,,,,,,,,,,"...sonicated for five cycles of 30 s on, 30 s off in 50 µL of 100 mM triethylammonium bicarbonate buffer supplemented with Complete Mini protease inhibitors (Roche, Basel, Switzerland)...",Non-genetic lab reagent/kit/consumable: Complete Mini protease inhibitors
S-Trap micro spin columns,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,S-Trap micro spin columns,Other,,,,,,,,,,,,,,,,,,,,"...After acidification with phosphoric acid and addition of the S-Trap binding buffer, the samples were applied to S-Trap micro spin columns (ProtiFi, Farmingdale, NY, USA)...",Non-genetic lab reagent/kit/consumable: S-Trap micro spin columns
UltraView Universal DAB detection kit,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,UltraView Universal DAB detection kit,Other,,,,,,,,,,,,,,,,,,,,...and detection with the UltraView Universal DAB detection kit (Roche)...,Non-genetic lab reagent/kit/consumable: UltraView Universal DAB detection kit
Dako EnVision kit,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Dako EnVision kit,Other,,,,,,,,,,,,,,,,,,,,"...The labeling was carried out using the peroxidase-based Dako EnVision kit (Agilent Dako, Santa Clara, CA, USA)...",Non-genetic lab reagent/kit/consumable: Dako EnVision kit
7-aminoactinomycin D,genetic_reagents,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,7-aminoactinomycin D,,,,,,,,,,,,,,,,,,,,,Live cells were isolated from dead cells by staining with 7-aminoactinomycin D (Biolegend; 420403; 1:100),Non-genetic lab reagent/kit/consumable: 7-aminoactinomycin D
SureSelect,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect,Other,,,,,,,,,,,,,,,,,,,,"library preparation with a Haloplex HS or SureSelect kits (Agilent Technologies, Santa Clara, CA, USA)",Non-genetic lab reagent/kit/consumable: SureSelect
CellTiter-Glo cell viability kit,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,CellTiter-Glo cell viability kit,,,,,,,,,,,,,,,,,,,,,Drug screening assays for all cell lines were carried out in a 384-well format using the CellTiter-Glo cell viability kit (Promega),Non-genetic lab reagent/kit/consumable: CellTiter-Glo cell viability kit
ADU-S100,genetic_reagents,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,ADU-S100,,,,,,,,,,,,,,,,,,,,,"50 μg of the STING agonist ADU-S100 (HY-12885B, MedChemExpress)",Non-genetic lab reagent/kit/consumable: ADU-S100
phospho-protein purification kit from Qiagen®,genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,phospho-protein purification kit from Qiagen®,,,,,,,,,,,,,,,,,,,,,Phospho-proteins were isolated from cell lysates using the commercially available phospho-protein purification kit from Qiagen®,Non-genetic lab reagent/kit/consumable: phospho-protein purification kit from Qiagen®
DNA extraction kit,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,DNA extraction kit,,,,,,,,,,,,,,,,,,,,,DNA was isolated from harvested tissues using DNeasy blood and tissue kit (Qiagen) according to the manufacturer's protocol,Non-genetic lab reagent/kit/consumable: DNA extraction kit
RNA extraction kit,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA extraction kit,,,,,,,,,,,,,,,,,,,,,Total RNA was extracted from cells and tissues using the RNeasy mini kit (Qiagen) following manufacturer's instructions,Non-genetic lab reagent/kit/consumable: RNA extraction kit
miRNAeasy kit,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,miRNAeasy kit,,,,,,,,,,,,,,,,,,,,,"Total RNA, including miRNA was extracted using the miRNAeasy kit (Qiagen Ltd, Crawley, West Sussex, UK)",Non-genetic lab reagent/kit/consumable: miRNAeasy kit
Mycoplasma detection reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Mycoplasma detection reagents,,,,,,,,,,,,,,,,,,,,,"cells were tested for mycoplasma using the Promokine Mycoplasma Test Kit I/C (Minerva Biolabs, Berlin, Germany)",Non-genetic lab reagent/kit/consumable: Mycoplasma detection reagents
cAMP detection reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,cAMP detection reagents,,,,,,,,,,,,,,,,,,,,,"cAMP levels in hiMGL cells were determined using the cAMP ELISA kit (Cayman Chemical, Ann Arbor, MI, USA)",Non-genetic lab reagent/kit/consumable: cAMP detection reagents
Cytokine detection reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cytokine detection reagents,,,,,,,,,,,,,,,,,,,,,"The MILLIPLEX MAP human cytokine/chemokine/growth factor panel A – immunology multiplex assay (HCYTA-60K, Merck) was used",Non-genetic lab reagent/kit/consumable: Cytokine detection reagents
RNA extraction kit,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,"total RNA was harvested with the RNeasy Mini Kit according to manufacturer's instructions (Qiagen Sciences, Germantown, MD)",Non-genetic lab reagent/kit/consumable: RNA extraction kit
BrdU staining reagents,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BrdU staining reagents,Other,,,,,,,,,,,,,,,,,,,,Cells were then treated with Zymed ® BrdU Staining Kit (Invitrogen),Non-genetic lab reagent/kit/consumable: BrdU staining reagents
Annexin V-FITC,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Annexin V-FITC,Other,,,,,,,,,,,,,,,,,,,,"The Annexin V-FITC Apoptosis Detection kit (Calbiochem, San Diego, Cat # PF032) was used following the manufacturer's instructions.",Non-genetic lab reagent/kit/consumable: Annexin V-FITC
DNA extraction kit,genetic_reagents,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,DNA was extracted from peripheral blood samples using PureGene Blood Core Kit B (Qiagen),Non-genetic lab reagent/kit/consumable: DNA extraction kit
Q5 Site-Directed Mutagenesis Kit,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Q5 Site-Directed Mutagenesis Kit,,,,,,,,,,,,,,,,,,,,,The R1320P mutation was created in a wild-type cDNA using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs).,Non-genetic lab reagent/kit/consumable: Q5 Site-Directed Mutagenesis Kit
TruSeq library construction kit,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq library construction kit,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA from tumor and normal samples were fragmented and used for Illumina TruSeq library construction (Illumina, San Diego, CA) according to the manufacturer's instructions.",Non-genetic lab reagent/kit/consumable: TruSeq library construction kit
AMPure XP beads,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AMPure XP beads,Other,,,,,,,,,,,,,,,,,,,,"DNA was purified using Agencourt AMPure XP beads (Beckman Coulter, IN) in a ratio of 1.0–0.9 of PCR product to beads.",Non-genetic lab reagent/kit/consumable: AMPure XP beads
SureSelect v.4,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect v.4,Other,,,,,,,,,,,,,,,,,,,,"Exonic regions were captured in solution using the Agilent SureSelect v.4 kit (Agilent, Santa Clara, CA).",Non-genetic lab reagent/kit/consumable: SureSelect v.4
cfDNA Extraction Kit,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cfDNA Extraction Kit,Other,,,,,,,,,,,,,,,,,,,,"cfDNA from each of the plasma samples was purified using a BioChain cfDNA Extraction Kit (BioChain, cat #K5011610) using the manufacturer's recommended protocol.",Non-genetic lab reagent/kit/consumable: cfDNA Extraction Kit
circulating nucleic acid kit,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,circulating nucleic acid kit,Other,,,,,,,,,,,,,,,,,,,,Cell-free DNA was extracted using the QIAGEN circulating nucleic acid kit (Catalog# 55114).,Non-genetic lab reagent/kit/consumable: circulating nucleic acid kit
TaqMan PCR Core REAGENTS Kit,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TaqMan PCR Core REAGENTS Kit,Other,,,,,,,,,,,,,,,,,,,,All PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) and either the TaqMan ® PCR Core REAGENTS Kit,Non-genetic lab reagent/kit/consumable: TaqMan PCR Core REAGENTS Kit
SYBR Green PCR Core Reagents kit,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SYBR Green PCR Core Reagents kit,Other,,,,,,,,,,,,,,,,,,,,or the SYBR ® Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems),Non-genetic lab reagent/kit/consumable: SYBR Green PCR Core Reagents kit
SureSelect bait library V1,genetic_reagents,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect bait library V1,Other,,,,,,,,,,,,,,,,,,,,"We used Agilent eArray to design our SureSelect bait library V1 (Agilent, California, USA), covering 106 genes",Non-genetic lab reagent/kit/consumable: SureSelect bait library V1
SureSelect bait library V2,genetic_reagents,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect bait library V2,Other,,,,,,,,,,,,,,,,,,,,The bait library V2 included 122 genes responsible for most of the cancer predisposition syndromes,Non-genetic lab reagent/kit/consumable: SureSelect bait library V2
TruSeq Stranded Total RNA,genetic_reagents,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,TruSeq Stranded Total RNA,,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were prepared using TruSeq Stranded Total RNA Sample Preparation kit (Illumina, San Diego, CA)",Non-genetic lab reagent/kit/consumable: TruSeq Stranded Total RNA
RNA isolation kit,genetic_reagents,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA isolation kit,,,,,,,,,,,,,,,,,,,,,RNA from primary astrocytes was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol,Non-genetic lab reagent/kit/consumable: RNA isolation kit
DNeasy mini kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNeasy mini kit,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA (gDNA) was extracted from both frozen tumour and blood tissues using the DNeasy mini kit (Qiagen, Valencia, CA, USA)",Non-genetic lab reagent/kit/consumable: DNeasy mini kit
KAPA Library Quantification Kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KAPA Library Quantification Kit,Other,,,,,,,,,,,,,,,,,,,,Accurate quantification for sequencing applications was determined using the qPCR-based KAPA Biosystems Library Quantification Kit,Non-genetic lab reagent/kit/consumable: KAPA Library Quantification Kit
miRNeasy mini kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,miRNeasy mini kit,Other,,,,,,,,,,,,,,,,,,,,"Total RNA containing both mRNA as well as microRNA fractions was extracted from the tissues using the miRNeasy mini kit (Qiagen, Valencia, CA, USA)",Non-genetic lab reagent/kit/consumable: miRNeasy mini kit
NEBNext Magnetic Oligo d(T)25 Beads,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NEBNext Magnetic Oligo d(T)25 Beads,Other,,,,,,,,,,,,,,,,,,,,Poly-adenylated RNAs were isolated using NEBNext Magnetic Oligo d(T)25 Beads,Non-genetic lab reagent/kit/consumable: NEBNext Magnetic Oligo d(T)25 Beads
TruSeq SBS HS v4 Kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq SBS HS v4 Kit,Other,,,,,,,,,,,,,,,,,,,,"Paired-end sequencing (25 million, 50-bp, paired-end reads) was performed using a 200 Cycle TruSeq SBS HS v4 Kit",Non-genetic lab reagent/kit/consumable: TruSeq SBS HS v4 Kit
RNA extraction kit,genetic_reagents,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,"RNAs were isolated using RNeasy mini kit (QIAGEN, Valencia, CA)",Non-genetic lab reagent/kit/consumable: RNA extraction kit
QIAamp Circulating Nucleic Acid kit,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,QIAamp Circulating Nucleic Acid kit,Other,,,,,,,,,,,,,,,,,,,,cfDNA was extracted from 2 to 8 mL of plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen),Non-genetic lab reagent/kit/consumable: QIAamp Circulating Nucleic Acid kit
Qubit dsDNA High-Sensitivity Assay kit,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Qubit dsDNA High-Sensitivity Assay kit,Other,,,,,,,,,,,,,,,,,,,,Extracted DNA concentration was measured using the Qubit dsDNA High-Sensitivity Assay kit (Thermo-Fisher),Non-genetic lab reagent/kit/consumable: Qubit dsDNA High-Sensitivity Assay kit
KAPA HyperPrep kit,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KAPA HyperPrep kit,Other,,,,,,,,,,,,,,,,,,,,cfDNA sequencing libraries were constructed from 10 to 60 ng of isolated DNA using the KAPA HyperPrep kit (Roche),Non-genetic lab reagent/kit/consumable: KAPA HyperPrep kit
CNMCS Compartmental Protein Extraction Kit,genetic_reagents,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CNMCS Compartmental Protein Extraction Kit,,,,,,,,,,,,,,,,,,,,,"Mouse tissues were collected and lysed with the CNMCS Compartmental Protein Extraction Kit (Millipore, 2145)...",Non-genetic lab reagent/kit/consumable: CNMCS Compartmental Protein Extraction Kit
8CPT cAMP,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,8CPT cAMP,,,,,,,,,,,,,,,,,,,,,"8-(4-Chlorophenylthio)adenosine 3′,5′-cyclic monophosphate (8CPT cAMP) (Abcam, catalog ab120424)",Non-genetic lab reagent/kit/consumable: 8CPT cAMP
ATP detection reagent,genetic_reagents,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,ATP detection reagent,,,,,,,,,,,,,,,,,,,,,CellTiter-Glo 3D Reagent Promega CAT#G968B,Non-genetic lab reagent/kit/consumable: ATP detection reagent
All-Prep Universal Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,All-Prep Universal Kit,Other,,,,,,,,,,,,,,,,,,,,"DNA and RNA were isolated from cell lines, human samples, or mouse allografts using the All-Prep Universal Kit (#80224, QIAGEN)",Non-genetic lab reagent/kit/consumable: All-Prep Universal Kit
Illumina Methylation EPIC Beadchip,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Illumina Methylation EPIC Beadchip,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA from human tumors were processed for methylation analysis using the Illumina Methylation EPIC Beadchip (#WG-317-1003, Illumina)",Non-genetic lab reagent/kit/consumable: Illumina Methylation EPIC Beadchip
Kapa Hyper Prep Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Kapa Hyper Prep Kit,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were prepared using the Kapa Hyper Prep Kit (#07962312001, Roche)",Non-genetic lab reagent/kit/consumable: Kapa Hyper Prep Kit
Nimblegen SeqCap EZ Human Exome Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Nimblegen SeqCap EZ Human Exome Kit,Other,,,,,,,,,,,,,,,,,,,,exome capture was performed using the Nimblegen SeqCap EZ Human Exome Kit v3.0 (Roche),Non-genetic lab reagent/kit/consumable: Nimblegen SeqCap EZ Human Exome Kit
TruSeq RNA Library Prep Kit v2,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq RNA Library Prep Kit v2,Other,,,,,,,,,,,,,,,,,,,,"Library preparation was performed using the TruSeq RNA Library Prep Kit v2 (#RS-122-2001, Illumina)",Non-genetic lab reagent/kit/consumable: TruSeq RNA Library Prep Kit v2
Chromium Single Cell 3′ Library & Gel Bead Kit v3.1,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Chromium Single Cell 3′ Library & Gel Bead Kit v3.1,Other,,,,,,,,,,,,,,,,,,,,Single-nuclei or single-cell RNA sequencing was performed using the Chromium Single Cell 3′ Library & Gel Bead Kit v3.1 on a 10× Chromium controller,Non-genetic lab reagent/kit/consumable: Chromium Single Cell 3′ Library & Gel Bead Kit v3.1
RNeasy Mini Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNeasy Mini Kit,Other,,,,,,,,,,,,,,,,,,,,"RNA was extracted from cell lines using the RNeasy Mini Kit (#74106, QIAGEN)",Non-genetic lab reagent/kit/consumable: RNeasy Mini Kit
iScript cDNA Synthesis kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,iScript cDNA Synthesis kit,Other,,,,,,,,,,,,,,,,,,,,"cDNA was synthesized from RNA using iScript cDNA Synthesis kit (#1708891, Bio-Rad)",Non-genetic lab reagent/kit/consumable: iScript cDNA Synthesis kit
Q-proteome cell compartment kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Q-proteome cell compartment kit,,,,,,,,,,,,,,,,,,,,,were fractionated using the Q-proteome cell compartment kit (Qiagen) following manufacturer's instructions,Non-genetic lab reagent/kit/consumable: Q-proteome cell compartment kit
Co-IP kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Co-IP kit,,,,,,,,,,,,,,,,,,,,,Co-IP experiments were performed without deviation from Co-IP kit protocol (Thermo Scientific),Non-genetic lab reagent/kit/consumable: Co-IP kit
Rneasy Mini Kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rneasy Mini Kit,,,,,,,,,,,,,,,,,,,,,"Total RNA of cultured cells was extracted using the Rneasy Mini Kit (Qiagen, Germantown, MD)",Non-genetic lab reagent/kit/consumable: Rneasy Mini Kit
Vybrant MTT cell proliferation assay kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Vybrant MTT cell proliferation assay kit,,,,,,,,,,,,,,,,,,,,,The Vybrant ® MTT cell proliferation assay kit quick protocol (Life Technologies) was employed,Non-genetic lab reagent/kit/consumable: Vybrant MTT cell proliferation assay kit
RNA isolation kit,genetic_reagents,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA isolation kit,,,,,,,,,,,,,,,,,,,,,Total RNA was isolated using the Direct-zol RNA Miniprep Kit (Zymo).,Non-genetic lab reagent/kit/consumable: RNA isolation kit
RNA library preparation kit,genetic_reagents,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA library preparation kit,,,,,,,,,,,,,,,,,,,,,Libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illumina),Non-genetic lab reagent/kit/consumable: RNA library preparation kit
Agilent SureSelect-XT reagents,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Agilent SureSelect-XT reagents,Other,,,,,,,,,,,,,,,,,,,,"DNA libraries were prepared using Agilent SureSelect-XT reagents (Agilent Technologies, Inc., Santa Clara, CA)",Non-genetic lab reagent/kit/consumable: Agilent SureSelect-XT reagents
Active RAS Pull-Down Kit,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Active RAS Pull-Down Kit,,,,,,,,,,,,,,,,,,,,,Ras-GTP assays were performed with the Active RAS Pull-Down Kit (Thermo Fisher),Non-genetic lab reagent/kit/consumable: Active RAS Pull-Down Kit
Qiagen DNA Blood Midi/Mini kit,genetic_reagents,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Qiagen DNA Blood Midi/Mini kit,Other,,,,,,,,,,,,,,,,,,,,"A total of 50 ng of genomic DNA purified from peripheral blood (Qiagen DNA Blood Midi/Mini kit, Qiagen GmbH)",Non-genetic lab reagent/kit/consumable: Qiagen DNA Blood Midi/Mini kit
Bond Polymer Refine Kit,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Bond Polymer Refine Kit,Other,,,,,,,,,,,,,,,,,,,,"Detection was performed using the Bond Polymer Refine Kit (DS9800, Leica Biosystems)",Non-genetic lab reagent/kit/consumable: Bond Polymer Refine Kit
FOXP3/Transcription Factor Fixation/Permeabilization kit,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FOXP3/Transcription Factor Fixation/Permeabilization kit,Other,,,,,,,,,,,,,,,,,,,,"cells first underwent fixation and permeabilization using the eBioscience ™ FOXP3/Transcription Factor Fixation/Permeabilization kit (Thermo Fisher Scientific, #00552100,)",Non-genetic lab reagent/kit/consumable: FOXP3/Transcription Factor Fixation/Permeabilization kit
TruSeq Stranded Total RNA Library Prep Gold kit,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq Stranded Total RNA Library Prep Gold kit,Other,,,,,,,,,,,,,,,,,,,,"samples were prepared with TruSeq ® Stranded Total RNA Library Prep Gold kit (Illumina, #20020599)",Non-genetic lab reagent/kit/consumable: TruSeq Stranded Total RNA Library Prep Gold kit
AG825,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,AG825,,,,,,,,,,,,,,,,,,,,,"Pharmacologic inhibitor experiments used 104 cells per well (NSC23766, 10 µM; AG825, 10 µM; Sigma, St. Louis MO)",Non-genetic lab reagent/kit/consumable: AG825
Rac1 activation Assay Kit,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rac1 activation Assay Kit,,,,,,,,,,,,,,,,,,,,,"Active Rac1 (Rac1-GTP) was determined by PAK1-PBD affinity chromatography (Rac1 activation Assay Kit, Millipore, Bedford MA)",Non-genetic lab reagent/kit/consumable: Rac1 activation Assay Kit
Ni-NTA resin,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ni-NTA resin,,,,,,,,,,,,,,,,,,,,,Recombinant wild-type Hsp90β was purified from the bacterial culture using a Ni-NTA purification system (Invitrogen),Non-genetic lab reagent/kit/consumable: Ni-NTA resin
Chariot protein delivery reagent,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Chariot protein delivery reagent,,,,,,,,,,,,,,,,,,,,,"4 μL of the lipophilic cell permeation agent Chariot (Active Motif, Carlsbad, CA, USA) in 100 μL ddH2O",Non-genetic lab reagent/kit/consumable: Chariot protein delivery reagent
patient-derived xenograft (PDX),patient_derived_models,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,CB17 SCID,MPNST,,,,,,"For MPNST M3 cell line-derived xenograft and patient-derived xenograft (PDX) studies, 2 × 10^6 and 3 × 10^6 cells, respectively",Vague PDX descriptor — no specific model ID or NF context: patient-derived xenograft (PDX)
patient-derived xenograft models,patient_derived_models,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NSG,MPNST,,,,,,efficacy studies in cell-line-derived and patient-derived xenograft models,Vague PDX descriptor — no specific model ID or NF context: patient-derived xenograft models
Patient-derived xenografts,patient_derived_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,MPNST,NRG,MPNST,,,,,,tumor pieces were acquired from MPNST patients at time of surgical resection and implanted subcutaneously,Vague PDX descriptor — no specific model ID or NF context: Patient-derived xenografts
